Osteoporosis treatment and fracture incidence: The ICARO longitudinal study

Osteoporosis International

Volumn 19, Issue 8, 2008, Pages 1219-1223

  Adami, S ^a   Isaia, G ^b   Luisetto, G ^c   Minisola, S ^d   Sinigaglia, L ^e   Silvestri, S ^f   Agnusdei, D ^g   Gentilella, R ^f   Nuti, R ^h  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^f Eli Lilly Italia SpA   (Italy)

^g ELI LILLY AND COMPANY   (United States)

^h UNIVERSITY OF SIENA   (Italy)

Author keywords

Alendronate; Fracture risk; Osteoporosis treatment; Raloxifene; Risedronate

Indexed keywords

ALENDRONIC ACID; CALCIUM; RALOXIFENE; RISEDRONIC ACID; VITAMIN D;

ADULT; ARTICLE; BODY MASS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; FRAGILITY FRACTURE; HUMAN; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT RESPONSE; VERTEBRA FRACTURE; VERTEBRA MALFORMATION; VITAMIN SUPPLEMENTATION;

ADULT; AGE FACTORS; AGED; ALENDRONATE; BODY MASS INDEX; BONE DENSITY CONSERVATION AGENTS; ETIDRONIC ACID; FEMALE; FRACTURES, BONE; HUMANS; ITALY; LONGITUDINAL STUDIES; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RALOXIFENE; TREATMENT FAILURE;

EID: 46649104759     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-008-0566-6     Document Type: Article

References (11)

1. Marcus R, Wong M, Heath H III, Stock JL (2002) Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev 23:16-37
2. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE, the Fracture Intervention Trial Research Group (1996) Randomised trial of effect of alendronate on risk fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541
3. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD, for the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 282:1344-1352
4. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R, on behalf of the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83-91
5. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR, for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282:637-645
6. Chesnut CH III, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D, for the PROOG Study Group (2000) A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study. Am J Med 109:267-276
7. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441
8. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459-446
9. Adami S, Isaia G, Luisetto G, Minisola S, Sinigaglia L, Gentilella R, Agnusdei D, Iori N, Nuti R, ICARO Study Group (2006) Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study. J Bone Miner Res 21:1565-1570
10. Agenzia Italiana per il Farmaco: AIFA. Available at: http://www. agenziafarmaco.it/
11. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077-2082